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3 
Abstract 
p53 is a transcription factor that plays a significant role in cell cycle regulation, 
senescence, and apoptosis. Through these mechanisms, p53 acts as a tumor suppressor. The p53 
protein has been widely studied for its link to human cancer, and is estimated to be mutated in 
~50% of all human cancers. This project focused on generating a p53-null A549 cell line using 
the genome editing technique CRISPR (Clustered Regularly-Interspaced Short Palindromic 
Repeats)-Cas9. The p53-null cell line will be used as a control for future projects that aim to 
identify the various roles of p53 and specific p53 isoforms, such as ∆Np53. The A549 cell line is 
a non-small cell human lung carcinoma line that exhibits wild-type p53 (WTp53). CRISPR-Cas9 
is a revolutionary genome-editing technique that greatly minimizes the cost, time, and difficulty 
associated with making site-specific genetic changes. It is becoming widely adopted as the 
standard for genome-editing projects and already has far reaching implications in research, 
biotechnology, agriculture, gene therapy, and medicine. The CRISPR-Cas9 technique uses a 20 
base pair-long programmable crRNA as a “guide” to direct the Cas9 enzyme to a specific 
location on the genome, where the Cas9 protein will create a double stranded break (DSB) in the 
DNA. Once this break is made, the cell can repair the damage via non-homologous end joining 
or homologous recombination. CRISPR-Cas9 was employed to generate a simultaneous knock-
in/knockout of mCherry and WTp53, respectively. The mCherry gene was inserted at the WTp53 
endogenous translational start site (TSS), thereby rendering WTp53 inactive and mCherry 
“active” whenever WTp53 would normally be expressed. After the initial transfection yielded 
low levels of mCherry fluorescence, focus shifted to next-generation CRISPR techniques that 
would increase the p53 knockout efficiency. One of these techniques included expressing and 
purifying the Cas9 protein in order to directly introduce it to target cells via electroporation. This 
approach has been shown to increase the success of site-specific genome editing for two main 
reasons: Firstly, by adding assembled Cas9 ribonucleoprotein (RNP) directly into the cell, this 
reduces the number of components needed to enter the cell from four to two. Secondly, it reduces 
off-target activity because there is a finite amount of Cas9 RNPs and they will be degraded in 
~24 hours. Cas9 was overexpressed in Rosetta 2 (DE3) E. Coli cells and was purified through a 
Ni-NTA affinity column followed by a Heparin Ion-Exchange column. The presence of Cas9 
throughout the purification was confirmed with Coomassie staining before and after each 
purification step, and as a final measure with a silver stain and western blot. The Cas9 
purification process has been optimized for future uses, and the assembly and electroporation of 
Cas9 RNPs will likely increase efficiency for any upcoming genome-editing projects within the 
Taatjes lab. 
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Introduction 
 TP53/p53   
 p53 is a tumor suppressor 
protein encoded by its gene, TP53. In 
its full length, p53 is 393 amino acids 
long and binds DNA as a tetramer 
(Figure 1) (Okorokov et al., 2006).  
p53 is regulated at the protein level 
and is expressed at constant low levels 
until the cell is stressed, at which point 
kinase activity leads to the release of 
p53 from its repressor, Mdm2 (Zheng 
et al., 2015). p53 controls cell cycle arrest, leading to senescence or programmed cell death 
(apoptosis). p53 has been shown to regulate numerous genes involved in cell growth arrest (p21, 
Gadd45), DNA repair (p53R2), and apoptosis (Bax, Apaf-1, PUMA, NoxA) (Zheng et al., 2015). 
It is estimated that TP53 is mutated in nearly 50% of human cancers. Because of its link to 
preserving the DNA of healthy cells, p53 is commonly referred to as “The Guardian of the 
Genome,” and is one of the most studied transcriptions factors of all time.  
 The gene, TP53, is 25,772 bases pairs long and is located on the short arm of chromosome 
17. It encodes for at least 15 isoforms and regulates over 100 other genes (Khoury et al., 2010). 
p53 is 43.6kDa in size and contains six main domains (Okorokov et al., 2006): 
1. (1-67) Transcriptional activation domain 
2. (67-98) Proline-rich domain 
3. (98-303) Core domain 
4. (303-323) Nuclear Localization containing domain 
 
Figure 1.  Model of how the p53 tetramer binds to DNA. N and C 
represent N- and C- termini, respectively (Okorokov et al., 2006). 
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5. (323-363) Oligomerisation domain 
6. (363-393) C-terminal basic domain 
 
p53 activity has also been linked to aging (Lin & Taatjes, 2014). p53 transcriptionally 
regulates the Mechanistic Target of Rapamycin (mTOR) pathway, by inducing the expression of 
genes (Sestrin1/2 & TSC2) involved in the suppression of mTOR.  mTOR has clear links to the 
aging process by accelerating the aging phenotype through stimulated ribosome biogenesis and 
mRNA translation (Goudarzi et al., 2014). Additionally, p53 has been shown to regulate ribosomal 
biogenesis, a key behavior in cancer proliferation. Studies that have inhibited ribosomal biogenesis 
lead to cell stress and activation of p53 (Goudarzi et al., 2014). Blocking the mTOR pathway with 
Rapamycin results in an increased lifespan for mammals (Feng et al., 2011).  
 p53 acts as a transcriptional activator for multiple genes (Feng et al., 2011). p53 also 
regulates its own levels by controlling the expression of Mdm2, which binds to unphosphorylated 
p53 leading to the protein’s nuclear export and degradation. When p53 is phosphorylated, this 
restricts Mdm2’s ability to bind, increasing the longevity of p53 (Feng et al., 2011). When DNA 
damage occurs, ATM kinases are activated, resulting in the phosphorylation of p53 and protection 
from degradation until the DNA is repaired (Zheng et al., 2015). This is one mechanism by which 
p53 remains viable in order to repair the DNA damage.  
 ∆Np53 
 ∆Np53 is a naturally occurring 
isoform of p53 that lacks the first 39 
amino acids from its N-terminal end 
(Figure 2). ∆Np53 levels increase in 
response to different types of cell stress, 
such as: ER stress, oxidative stress, and/or 
Figure 2. Schematic of WTp53 versus ∆Np53. HDM2 is 
a ubiquitin ligase that tags p53 for degradation. TA1: 
transactivation domain 1, TA2: transactivation domain 2, 
PxxP: Proline-rich domain, OD: Oligomerisation domain, 
CTR: C-terminal region (Levandowski, 2015). 
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serum deprivation (Lin & Taatjes, 2013). The isoform is translated via an internal ribosomal entry 
site (IRES), or through alternative splicing. ∆Np53 lacks the Mdm2 binding site present on 
WTp53, and therefore its longevity is not regulated by the mechanisms regulating WTp53 (Lin et 
al., 2013). 
Because p53 is a tetramer, if WTp53 and ∆Np53 are co-expressed, their subunits combine 
in random, creating a mixture of ∆Np53:WTp53 in the ratios: 0:4, 1:3, 2:2, 3:1, and 4:0. This 
resulting mixture can make it challenging to identify the distinct role of WTp53 from its isoform 
∆Np53. Studies have shown that ∆Np53 and WTp53 co-expression results in an accelerated aging 
phenotype in the mouse model (Pehar et al., 2010). Earlier death rate, increased levels of 
osteoporosis, and decreased learning ability were seen in a study examining ∆Np53:WTp53 
genotypes in mice compared to the wild type controls (Pehar et al., 2010). 
mCherry 
mCherry is a monomeric red fluorescent protein with an excitation wavelength of 587 nm 
and an emission at 610 nm. mCherry is 27kDa in weight and exhibits a ß-barrel shape with a 
chromophore and its center. 
There is an alpha-helical 
domain which threads itself 
through the barrel’s center. 
The mCherry gene is 1304 
base pairs long and served as 
the gene to be inserted at the 
p53 endogenous TSS using 
CRISPR-Cas9. 
Figure 3. Structural model of mCherry florescent protein  
(http://zeiss-campus.magnet.fsu.edu/articles/probes/anthozoafps.html). 
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A549 cell line 
The A549 cell line are non-small cell human lung carcinoma cells. They exhibit epithelial 
morphology and can be easily transfected using standard lipofectamine protocols. The population 
doubling time is approximately 22 hours. Most cells had two X and two Y chromosomes. These 
cells contain WTp53 on both alleles and are used to examine the role and function of p53 and its 
many isoforms within the Taatjes lab. In order to observe how ∆Np53 and WTp53 behave, it 
became necessary to generate a p53-null cell line within the same cell line that was being used in 
the ∆Np53 study. A quick, efficient and precise genetic-editing technique was required in order to 
generate the knockout.  
 Known p53-null cell lines 
 Although p53 plays a significant role in gene regulation, it is not an essential protein for 
the viability of all cells (Soussi, 2010). There are existing p53-null cell lines that have been derived 
from human tissue. Additionally, the term “p53-null” can prove to be ambiguous in both everyday 
use and in literature. In some contexts, the term “p53-null” has been used to describe cell lines that 
have mutated p53 genes but may exhibit normal or partial p53 responses (Soussi, 2010). In this 
context, a true “p53-null” cell line exhibits no p53 behavior. The following table encompasses a 
few of these known p53-null lines and their associated cancer type:  
Cell line Cancer 
Hep3B Hepatocellular carcinoma 
KATO III Gastric carcinoma 
NCl-H1299 Non-small cell lung carcinoma 
Soas-2 Osteosarcoma 
LZ-Z308 Glioblastoma 
HL-60 Promyelocytic leukemia 
MDA - MB-157 Breast carcinoma 
 
 
Table 1. Table listing multiple known p-53 null cell lines and the human cancer from which they were derived. 
(p53.free.fr/Database/Cancer_cell_lines/cell_lines_1.0.pdf) 
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 To the Taatjes’ lab’s knowledge, a p53-null A549 cell line has not been generated before, 
which warrants further exploration into A549’s viability and behavior as a p53-null line. 
CRISPR-Cas9 
CRISPR-Cas9 is a revolutionary genome-
editing technology discovered by 
studying how bacteria defend themselves 
from viruses and other infectious foreign 
DNA through the process outlined in 
Figure 4 (Mojica et al., 2005; Ebina et al., 
2013). If a bacterium is infected with a virus, a CRISPR-associated (Cas) polymerase copies the 
viral DNA in short segments and inserts sequences of the viral DNA into a region of the bacteria’s 
genome containing highly 
repetitive DNA. This region of 
repetitive DNA is referred to as 
the Clustered Regularly 
Interspaced Short Palindromic 
Repeats (“CRISPR”) array. 
This enables the bacteria to 
keep a history of previous 
infections. The “saved” viral 
DNA can later be transcribed to act as “guide” RNA, which complementarily binds to invading 
viral DNA, directing the Cas9 nuclease to cleave it rendering the virus ineffective (Oost et al., 
2014). This technique results in a robust, adaptive defense mechanism against infection.  
Figure 4. Overview of bacteria’s adaptive immunity against foreign 
DNA (https://www.wageningenur.nl/en/show/CRISPRCas). 
Figure 5. Cas9 RNP complex binding to DNA upstream of 
the PAM sequence (Doudna et al., 2014). 
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CRISPR’s immense potential lies in its ability to be harnessed for precise genetic-editing 
purposes. There are two main components to the CRISPR-Cas9 system: The “sgRNA” and the 
Cas9 protein. SgRNA stands for “single guide RNA” and is a single complex engineered from two 
pieces of RNA: the tracRNA and crRNA. CrRNA is programmable up to 20 base pairs and is 
responsible for CRISPR-Cas9’s location-specific activity. The crRNA Watson-Crick base-pairs 
with the target DNA, and the tracRNA acts as a bridge between the crRNA and the Cas9 enzyme 
(Figure 5). One requirement for CRISPR-Cas9 is the presence of a PAM sequence, which stands 
for “Protospacer Adjacent Motif,” and is the sequence NGG, where N is any base and G is 
Guanine. The PAM sequence must be directly downstream of the target DNA in order for Cas9 to 
bind DNA (Doudna et al., 2014). Cas9 is a large (~160kDa) nuclease responsible for creating a 
double-stranded break (DSB) in DNA. Once the break has been made, natural DNA repair 
mechanisms can mend the break, often inserting a few extra nucleotides, effectively knocking-out 
the gene if the additional bases result in a frame-shift mutation; this is called non-homologous end 
joining (NHEJ) and can be a useful technique for generating a knockout (Figure 6). Alternatively, 
homologous recombination (HR) occurs when a double stranded break is repaired using 
homologous DNA, usually derived from the cell’s homologous chromosome (McClendon et al., 
2016). Using HR, foreign or “template 
DNA” can be inserted at the DSB, but 
only if the template DNA is flanked by 
the same DNA sequences that frame the 
DSB (Guilinger et al., 2014; Doudna et 
al., 2014). This project used a plasmid 
Figure 6.  NHEJ vs. HR (https://www.genoway.com/crispr-
cas9/nucleases.htm). 
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containing mCherry (1.3 kb) flanked by 1.5 kb of homologous DNA sequences directly upstream 
and downstream of the TSS of WTp53 in A549 cells.  
 The applications for CRISPR-Cas9 are seemingly endless, and are already being explored 
in the realms of gene therapy, agriculture, medicine, livestock, molecular biology and drug 
targeting (Ebnia et al., 2013; Doudna et al., 2014). The initial transfection used 1 tracRNA, 1 
crRNA, 1 Cas9 plasmid, and 1 repair template DNA plasmid. The transfection of four components 
is not ideal for a number of reasons. Firstly, the cells must be exposed to a high level of stress in 
order to “take up” four separate pieces of foreign DNA and RNA. Secondly, by transfecting the 
Cas9 plasmid, in essence the cell is continually expressing Cas9. As the plasmid is continuously 
transcribed and translated, Cas9 levels stay at a relatively high level until the plasmid is degraded. 
One of the main problems with the CRISPR-Cas9 method is the possibility of off-target cutting, 
which is more likely to occur when Cas9 levels are held at a higher concentration for a relatively 
long period of time (Cho et al., 2014). Off-target cutting is detrimental to the health of the cell and 
may compromise the accuracy of the affected outcomes or goals of the project. Off-target activity 
is the main reason why research using CRISPR-Cas9 in human therapeutics is currently on hold, 
and there is a general consensus that the technology is not safe enough yet to use in viable human 
embryos (Cyranoski, 2015).  
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Cas9 
The Cas9 enzyme is approximately 
160kDa and is a part of the Cas family of 
proteins originating from bacteria. The Cas9 
enzyme has four main domains shown in 
Figure 7. RuvC (grey) cleaves the non-target 
strand. HNH (cyan) cleaves the target strand. 
Guide RNA Domain (blue) is responsible for 
binding to the guide RNA, specifically the 
tracRNA component, which leads to Cas9’s 
site-specific binding on DNA. PI (PAM Interacting) Domain (orange) binds to the downstream 
PAM sequence (NGG) and is the most critical component for Cas9-DNA binding (Nishimasu et 
al., 2014). The double stranded break is generated 3-4 nucleotides upstream from the PAM 
sequence. As indicated, Cas9 has two catalytic sites, each one is responsible for the cleavage of 
one strand of DNA. Mutating aspartate to alanine in the RuvC domain successfully converted the 
enzyme to a nickcase that only cleaves one strand of DNA. This engineered nickcase is called 
SpCas9n and is currently being studied for its potential applications (Cong et al., 2013). 
pMJ915 
pMJ915 is the recombinant plasmid designed by the Doudna Lab and supplied by Addgene 
that contains the Cas9 gene under control of the T7 promoter (Appendix A). The Cas9 contains 
6xHis-MBP fusion tag on its N-terminal end. The polymerase T7 is specific to the T7 promoter 
and will only transcribe DNA downstream of its promoter. The total vector size is 10,124 bp in 
length. The plasmid confers ampicillin resistance and is designed for expression in bacteria. 
Figure 7. Cas9 crystallography structure. Adapted 
from Anders et al in the 2014 Nature paper. 
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Techniques to improve efficiency  
There are a number of proposed and implemented techniques used to increase CRISPR 
Cas9’s efficiency in cells and to minimize off-target activity. Synchronizing the cell’s cycle 
increases the efficiency of CRISPR activity because the cells can be programmed to all enter 
metaphase simultaneously so the DNA will be bound less tightly to histones and the chromatid in 
anticipation of replication (Lin et al., 2014). This makes the DNA more accessible to the CRISPR-
Cas9 complex and leads to increased efficiency of targeted cleaving.  
 Other techniques to reduce off-target cutting include truncating the length of the crRNA 
(<20 bp), which has been shown to decrease off-target mutagenesis by 5,000 fold. Additionally, 
inhibiting one of the catalytic sites on Cas9 so it cleaves just 1 strand (SpCas9n) has been shown 
to increase efficiency (Fu et al., 2014; Shen et al., 2014). Instead of generating a double stranded 
break, the mutated Cas9 cleaves a single strand of DNA but is used in tandem with another Cas9 
nickcase acting on the opposite end of the target DNA. The target DNA is then “flanked” by two 
Cas9 enzymes, each mutated in one catalytic site. This increases the site-specific accuracy up to 
1,000-fold, in turn reducing cell death, as it is much easier for the cell to repair a single strand 
DNA break than a double stranded break in the event of off target effects (Ran et al., 2013). 
The next generation efficiency-improving CRISPR technique pursued by this project was 
to directly add the Cas9 ribonucleoprotein (RNP) complex into the cells as opposed to transfecting 
the Cas9 plasmid. This will limit the presence of Cas9 in the cell to approximately 24 hours; it has 
been shown that Cas9 will be degraded by that time (Doudna et al., 2014). In order to directly 
insert the Cas9 protein it must be pure and catalytically active. Purified Cas9 can be purchased but 
it is costly and a short-term solution, so the decision was made to express and purify Cas9 so it can 
be used in future genome-editing experiments via RNP assembly and electroporation. 
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Results 
 Project Overview 
 The project was divided into two parts. Part I attempted to generate a p53 knockout using 
CRISPR-Cas9 in A549 cells, and Part II expressed and purified the Cas9 protein. Part II came 
about in the wake of low efficiency after the initial transfection, so the focus of the project shifted 
to next generation CRISPR-Cas9 techniques to increase efficiency. 
Part I: Generate p53 knockout via Homologous Recombination of mCherry 
Day 1 of the transfection began when 
A549 non-small cell human lung carcinoma 
cells were grown up to confluence. To 
transfect, appropriate transfection solutions 
(serum free media, crRNA, tracRNA, Cas9 
plasmid, mCherry plasmid, & DuoFECT) 
were added at appropriate concentrations. 
The reagents incubated for 20 minutes while 
the cells were prepared at their desired 
concentration (100,000 cells per well on 24-
well plate). 52uL of transfection reagent 
(containing all CRISPR-Cas9 components 
described above) were added to 448uL of 
cell preparation (~200,000 cells/mL), and 
allowed to incubate for 48 hours. On Day 3, 
Figure 8. Part 1 Flowchart. p53 knockout/mCherry 
knock-in using CRISPR-Cas9 at the endogenous p53 
translational start site (TSS) in A549 cells. 
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the transfected cells were selected by adding 1.5 ug/mL puromycin. On Day 5, the selection media 
was removed and replaced with regular media. 
The media was replaced every two days, and 
the surviving cells were grown until confluent and 
passaged to 60mm plates. Next, Flow Cytometry was 
used to select for cells exhibiting mCherry 
fluorescence with a negative control reading used to 
create a “gated” positive region (Figure 9). The 
negative control sample contained all the reagents 
minus the mCherry plasmid. Only 0.012% of cells 
fluoresced out of the thousands that were imaged. 
The cells that were selected for positive fluorescence 
(0.012%) were grown up as single-cell colonies in 96-well plates. All single-cell colonies 
exhibiting growth were imaged using 16 photos/well in the Spencer Lab, and all wells with signs 
of fluorescence were expanded. The final percentage of cells exhibiting fluorescence are below:  
Figure 9. Flow Cytometry Data. “Gated” 
positive region delineated in red. Each dot 
represents the reading of one cell. X-axis: 
Fluorescence detected (log scale). Y-axis: Side 
Scatter - angle of orthogonal light scatter 
(linear scale). 
Figure 10. Part 1 Overview of Transfection Efficiency. Four components were transfected into A549 cells. The 
resulting cell growth data was obtained. Approximately 30% of each crRNA group grew to be passaged to 
undergo Flow Cytometry (FC). ~ 0.012% of cells exhibited fluorescence and were grown up as single cell 
colonies on 96-well plates for further imaging. Further imaging revealed ≤ 1% of cells “strongly” fluoresced.  
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Based on the low levels of fluorescence (≤1% of 0.012%) and the weakness of the 
fluorescence it was decided that the efficiency of the transfection was too low to continue. The 
project then shifted to expressing and purifying the Cas9 protein to increase genome editing 
efficiency. 
Part II: Expression & Purification of Cas9 protein 
 Rosetta 2 (DE3) E. Coli cells were grown 
up in order to overexpress Cas9. A mini-prep 
purified the plasmid obtained from Addgene and 
the Cas9 plasmid was transformed into Rosetta 2 
(DE3) cell lines. 4 L of Terrific Broth were used 
throughout the transformation to maximize Cas9 
expression because its expression is typically low. 
The OD600 (optical density) is an indication of 
bacterial growth, and once it reaches 0.8-1.0, the 
plasmid can be induced through IPTG addition, as 
the Cas9 plasmid is under control of the lac operon. 
LacL inhibits the promoter, but IPTG binds to 
LacL, releasing it from the promoter and allowing for the transcription of downstream (Cas9) 
genes (Marbach et al., 2011). The OD600 measurements and the moment of IPTG addition are 
shown in Appendix B & C. In Figure 12, uninduced (U) and induced (I) samples were taken at 
increasing concentrations and run on a polyacrylamide gel stained with Coomassie to show the 
appearance of an induction band, which is Cas9. 
 
Figure 11. Part 2 Flowchart. Cas9 Purification. 
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Ni-NTA column  
 The Ni-NTA purification 
method is effective in purifying 
proteins that contain a series of 
Histidine residues. The Cas9 in 
question has a 6xHis-MPB fusion 
tag on its N-terminal end, which 
qualifies it to be used in a Ni-NTA 
purification. The Ni-NTA column is composed of beads attached to the molecule NTA, 
nitrotriaceticacid, which is a chelating ligand in the presence of an immobilized Ni2+ ion. The 
negative neighboring histidine residues interact with the column’s complex through coordination 
Figure 12. Induction Gel on SDS-PAGE 7.5% polyacrylamide gel in Coomassie stain. M: “Marker;” U: 
“Uninduced;” I: “Induced.” U and I pairs were loaded at increasing volumes from 3 uL, 5uL, 10uL to 15 uL, left 
to right. The appearance of the Cas9 band indicates a successful induction. 
Figure 13. Ni-NTA coordination bonds interacting with water and 
histidines (http://www.gentoprice.com/ni-ida-agarose.htm). 
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bonds. The coordination 
complex is shown in Figure 
13. A coordination bond is 
similar to a covalent bond 
with the exception that both 
shared electrons come from 
the same atom. The Ni-NTA 
column was performed in a batch purification using Ni-NTA beads, but was rocked for a period 
of 10 minutes per elution as opposed to using a vertical flow-through column. Increasing 
concentrations of imidazole (which structurally resembles histidine) were used to compete with 
histidine’s affinity to the NTA complex, eventually washing out the desired Cas9, shown in the 
Coomassie stained gel under “Elution” (Figure 14). 
100kD Amicon Filter 
 Once the elution containing Cas9 was collected from the Ni-NTA batch, it was condensed 
via a 100kDa Amicon filter. The elution was placed in the top portion of the condenser and 
centrifuged until the sample was concentrated from ~10mL to 2x 500 uL samples. All protein less 
than 100kDa in size is free to pass through the 
membrane, whereas larger proteins, such as Cas9, 
will not flow through the membrane, allowing it to 
remain at the top of the tube in the solution at a 
higher concentration. During this concentration 
process, a wispy white precipitant began to form in 
the solution. This was both a positive and negative 
Figure 14. Ni-NTA batch duplicate elutions on SDS-PAGE 7.5% 
polyacrylamide gel in Coomassie stain. M: “Marker;” Buffer 1: 0 mM 
Imidazole; Buffer 2: 10 mM Imidazole, Elution: 300 mM Imidazole. 
Figure 15. Schematic of Amicon 100kDa 
protocol (https://www.merckmillipore.com). 
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sign. It was positive because it indicated protein was present in the sample. It was negative because 
it meant protein was “crashing” out of the solution, which means the protein’s conformation 
changed so its hydrophobic residues, which usually reside on the inside of its 3D shape, began 
flipping outward. When hydrophobic resides come into contact with polar solution, they react 
insolubly, lending the protein to “crash out.” This can occur when the ion concentration is high as 
this leads to an “ion shield” around the protein, which prevents the protein’s hydrophilic residues 
from interacting with water molecules. Instead, the “ion shield” permits the protein to interact with 
other proteins, which eventually aggregate together and precipitate. Once a protein crashes out of 
a solution, it is lost to the rest of the purification process as it is energetically unfavorable for it to 
go back into the solution.  
TEV Protease 
 Once the elution was concentrated, TEV 
protease was added to the sample to cleave off the 
6xHis-MPG fusion tag to continue the 
purification. TEV protease was isolated from the 
Tobacco Etch Virus and is a Cysteine protease 
that specifically recognizes the sequence 
ENLYFQ/S: Glu-Asn-Leu-Tyr-Phe-Gln-Ser and 
cleaves between Gln and Ser. The TEV Protease 
was added overnight at a concentration of 1ug per 
~50 ug of substrate. A polyacrylamide gel was 
stained with Coomassie gel (Figure 17) was run 
as a confirmation for its effectiveness. 
Figure 17. TEV Protease activity on SDS-PAGE 
7.5% polyacrylamide gel in Coomassie stain. 
Figure 16. TEV Protease Graphic 
(https://www.biomol.com/tev-protease.html?id=1211). 
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Heparin Ion Exchange Column 
Once the sample had been cleaved of its 6xHis-MBP tag, it 
was run through a HiTrap Heparin Ion Exchange Column. This ion 
exchange column is a cation-exchange column, meaning it contains 
negatively charged resin that ionically binds with molecules that 
are positively charged (Figure 18). A key importance is that the 
protein of interest must carry a net positive charge at the working 
pH, and the column must carry a net negative charge at the same 
pH. The difference of charges between the protein of interest and 
the resin at the working pH determines the strength of the binding. 
The pI (Isoelectric point) of Cas9 is ~pH 8. This is the pH at which its net overall charge is neutral. 
When the working pH < pI, the overall charge of the protein will be positive, as there are more H+ 
ions in the solution interacting with the protein’s residues. In this case the working solution is 
pH=7.5, so the overall charge of Cas9 is positive, hence, the column’s resin should be negative. 
Increasing salt concentrations begin to compete with the resin-protein interactions and eventually 
the protein is eluted as the cations in the salt solution form ionic bonds with the resin and the 
charged residues on the protein. 
As the salt concentration gradient increased, any remaining uncleaved Cas9 sample eluted 
first and the cleaved Cas9 sample eluted second, as indicated by the peaks on Figure 19. The peaks 
show absorbance at wavelength = 280 nm, which is where Tryptophan and Tyrosine absorb. Cas9 
contains 7 Tryptophan’s and 54 Tyrosine’s, so it is a good candidate for this method of detection 
(Nishimasu, 2014). The fractions with the highest peaks were combined and sampled on a silver 
stain gel, shown in Figure 20. Silver stain can be 200x more sensitive than Coomassie stain, so it 
Figure 18. Cation exchange 
column (Freeman et al., 2012). 
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was a strong indication that the final Cas9 sample was remarkably pure (Bio-Rad). A final 
affirmation of Cas9’s presence was confirmed via a western blot, using antibodies specific to Cas9, 
shown in Figure 21. 
  
 
 
 
 
 
 
 
 
Figure 19. Elution peaks from HiTrap Heparin Ion-Exchange column with the uncleaved Cas9 eluting first and 
the cleaved Cas9 eluting second. Left Y-axis: UV=280 nm absorbance (mAU) reading. X-axis: Fractions 
collected. Right Y-axis: % of total solution.  
Figure 20. Silver stain of peak fractions. A: uncleaved 
Cas9. B: cleaved Cas9. Fractions 38-41 were combined as 
“Shoulder” sample and fractions 42-45 were combined as 
“Pure.” Both were run on western blot shown in Figure 21. 
Figure 21. Western blot of 
combined fractions selected from 
the silver stain. A: uncleaved Cas9. 
B: cleaved Cas9. 
 
ß A 
ß B 
ß A 
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Discussion 
 The original transfection, which relied on transfecting four separate components: 1 crRNA 
1 tracRNA, 1 Cas9 plasmid and 1 mCherry plasmid, was low in efficiency (<1% of 0.012% of 
cells fluoresced). As an alternative practice, the direct electroporation of Cas9 was discussed as a 
possible way to increase efficiency. The second half of the project focused on the expression and 
purification of Cas9. Throughout the purification, Cas9 proved to be a robust enzyme, and although 
every step was preformed at 4Cº, it remained resilient with the exception of minor “crashing out” 
during its concentration. Samples were taken for SDS-PAGE analysis before and after every 
purification step to ensure it hadn’t been lost throughout the process.  
 The direct electroporation of Cas9 RNP will result in finite levels of Cas9, resulting in less 
off-target cutting. A study showed that by direct electroporation, Cas9 was degraded in 24 hours: 
contrast this with transfecting its plasmid, which expresses Cas9 for several days (Kim et al., 
2014).  Additionally, by reducing the number of components needed to be transfected from 4 to 2, 
this increases the likelihood of a successful overall transfection. By comparing the two 
transfections side-by-side and checking for fluorescence via Flow Cytometry and visual imaging, 
one would anticipate an increase in efficiency. A recent study that delivered the Cas9 RNP 
complex to human cells saw on-target mutations as high as 79% of the time with a reduction of 
off-target activity as compared with transfecting plasmids (Kim et al., 2014).  The expression and 
purification of Cas9 was successful and has been optimized for future uses. The direct assembly 
of the Cas9 RNP complex is a next-generation CRISPR-Cas9 technique that yields higher 
efficiencies, and will likely be invaluable for future genetic-engineering projects in the Taatjes lab. 
Purifying Cas9 was the first step to assembling the complex, and its use will hopefully provide key 
insights into the importance of p53 and help demystify the roles of its many isoforms. 
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Future Directions 
 Now that a purification protocol has been 
established, optimized, and proven effective, the next 
steps are to first validate the purified Cas9 activity in 
vitro, then to repeat the purification process with a higher 
initial volume of cells to end with a greater Cas9 yield. A 
single transfection typically calls for ~30ug of Cas9. 
Once an adequate amount of Cas9 has been purified and 
validated, the ribonucleoprotein complex (RNP), will be 
assembled and added into the target cells directly via 
electroporation, along with the repair template, mCherry. 
This protocol would ideally be done side-by-side with the original transfection, which was reliant 
on transfection of 4 separate components. Ideally, by direct electroporation of the Cas9 RNA 
complex and the mCherry plasmid, efficiency of the mCherry insert and resulting p53 knockout 
will increase significantly.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Flowchart of RNP assembly 
protocol (Doudna et al., 2014). 
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Methods  
A549 cell culture and transfection 
 
Day 1: Transfect Cells with crRNA, tracRNA, template plasmid, and Cas9 plasmid. Day 3: Select 
with Puromycin. Day 5: Remove selection media. Day 12-19: Sort cells for mCherry marker into 
single cell colonies in 96 well plates with conditioned media. Day 19-26: Look at single cell 
colonies to ensure one colony is in each well. Grow cells up enough to extract DNA and freeze 
down tubes, which takes at least 2-3 more weeks. Spencer lab imaged cells 16 photos/well to see 
which single cell colonies express mCherry. 
 
Flow Cytometry 
 
Cells were washed twice with PBS and harvested with trypsin. Trypsin was quenched and the 
solution was centrifuged at 1300rpm for 5 minutes. The cells were then resuspended in 1 mL of 
media and filtered through a CellTric 50 uM filter. The cells were transferred into 5 mL Falcon 
round-bottom polypropylene tubes. The Falcon tubes were inserted into a MoFlo Legacy Flow 
Cytometry machine and sorted at 561 nm. 
 
pMJ915 Transformation into Rosetta 2 (DE3) cells 
 
Added 30 uL of Rosetta cells per reaction. Pre-chilled BD Falcon polypropylene round-bottom 
tubes on ice. Thawed cells on ice, and added 50 ng of experimental DNA (pMJ915). Swirled the 
tube gently and incubated on ice for 30 minutes. Heat-pulsed the tubes in a 42 ̊C water bath for 30 
seconds. Incubated on ice for 2 minutes. Added 970 uL of LB to tube and incubated at 37 ̊C on 
shaker for 1 hour. Plated 100 uL of 1 mL solution on pre-warmed plate. Spun down the remaining 
solution after transferring to 1.5 mL Eppendorf tube at less than 3000 rpm. Resuspended the pellet 
in 100uL of LB and plated on pre-warmed amp plates. Incubated overnight at 37 ̊C and selected 
colonies for induction the next day. 
 
E. coli cell culture and Cas9 protein expression 
 
Overnight culture was made by selecting colonies containing the Cas9 plasmid pMJ915 
(containing antibiotic resistance and an IPTG inducible promoter) in a small sample of Terrific 
Broth (800 mL of distilled water, 12 g Tryptone, 24 g Yeast extract, 4 mL Glycerol, adjust to 900 
mL with distilled H2O). Autoclaved and let cool to room temp, and adjusted to 1000 mL with 
filtered sterilized 100 mL solution of 0.17 M KH2PO4 and 0.72 M K2HPO4) (TB) overnight at 
37 ̊C. Ampicillin and chloramphenicol were added in final concentrations of 0.1 mg/mL to select 
for antibiotic resistant strains. The overnight culture was then transferred to a larger flask 
containing Terrific Broth and antibiotics and incubated at 37 ̊C for approximately 20 hours. The 
cells were subcultured at 1:100 ratios into 1 L of TB containing 100ug/ml of amp and 30 ug/ml of 
chloramphenicol. The cells were incubated for approximately 4 hours until their ocular density 
(OD600) reached 0.8-1.0. The culture was then chilled in an ice bath and IPTG was added to 0.5 
mM to induce protein expression. The culture was grown overnight in an 18 ̊C shaker. The culture 
was transferred to 1-L centrifugal bottles and spun down at 3500g for 10 minutes at 4 ̊C. The cells 
were resuspended in 50 mL or Buffer 1 (20 mM HEPES, pH 7.5, 1 M KCl, 10 % glycerol, 1 mM 
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TCEP and 0.1 % Triton X-100) per liter of culture. 1mM of PMSF was added. The suspension was 
stored at -80 ̊C until the purification process began. 
 
Isolation of cell lysate 
 
All purification steps were performed at 4 ̊C. Cells were thawed under cold tap water and 
transferred to 100mL beaker containing a stir bar. The beaker was placed on ice. One tablet of 
Roche EDTA-free protease inhibitor was added per 50 mL of suspension. The cells were lysed via 
sonication (power output 5, pulse-on 1 seconds, pulse-off 1 seconds, for a total of 2 minutes) under 
constant stirring. The lysate was centrifuged at 15,000 g for 45 minutes. 
 
Ni-NTA batch purification 
 
1 mL of Qiagen Ni-NTA beads were equilibrated in a 50 mL conical tube by washing with water. 
The beads were centrifuged at 3000 g for 5 minutes to collect. A 10 uL lysate sample was taken 
for SDS-PAGE analysis. The remainder of the lysate incubated with the beads on an orbital shaker 
on low speed for 30 minutes. The tube was centrifuged at 3000 g for 5 minutes to collect the beads. 
The beads were washed with 20 column volumes of Buffer 1, with low-speed rocking for 5 minutes 
before centrifugation to collect the beads between each wash. The beads were then washed with 
20 column volumes of Buffer 2 (20 mM HEPES, pH 7.5, 1 M KCl, 10 % glycerol, 1 mM TCEP 
and 10 mM imidazole, 0.2 um filtered and degassed). The protein was then eluted in Buffer 3 (20 
mM HEPES, pH 7.5, 0.5 M KCl, 10 % glycerol, 1 mM TCEP and 300 mM imidazole, 0.2 um 
filtered and degassed). The elution was rocked in Buffer 3 for 15 minutes in 10 column volumes, 
equaling a total of 10 mL. Elution fractions were sampled and run on SDS-PAGE in Figure 14. 
The 10 mL of elution was condensed to 2 samples of 500uL using 100kDa Amicon filter cuvettes. 
TEV protease was added to cleave the 6xHis tag and MBP fusion at 4 ̊C overnight.  
 
Ion Exchange Chromatography 
 
A 5-mL HiTrap Heparin HP column was connected to a GE FPLC machine and the flow rate was 
set to 2 mL/min for the duration of the purification. The column was equilibrated with 10 column 
volumes of Buffer 4 (20 mM HEPES, pH 7.5, 300 mM KCl, 10 % glycerol and 1 mM TCEP). 1 
mL of Ni-NTA Cas9 elution was diluted in 9 mL of Buffer 4 for a total of 10 mL to bring the KCl 
concentration to approximately 300 mM. The solution was then filtered with a 0.45 um syringe 
filter and injected into the column. The column was washed with 10 column volumes of Buffer 4 
until the OD280nm reached baseline. The FPLC was programmed to elute Cas9 by a 20 column 
volume linear gradient to 100% of Buffer 5 (20 mM HEPES, pH 7.5, 1 M KCl, 10 % glycerol and 
1 mM TCEP) at 2ml/min. Every third fraction throughout the entire elution and every fraction 
where peaks occurred were taken for SDS-PAGE analysis. The fractions were combined and 
concentrated by Amicon 100kDa filter. 
 
Amicon 100kDa Concentration 
 
Added up to 4.5 mL of elution to the top portion of the Amicon tube. Centrifuged at 3000 rpm for 
5 minute pulses until 500 uL elution remained. Saved and sampled flow-through to run on SDS-
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PAGE for analysis. Solutions with higher glycerol content will flow much slower through the 
membrane and require longer periods of centrifugation. 
 
Coomassie stain 
 
A 7.5% polyacrylamide SDS-PAGE gel was run with the samples. The gel was then placed in blue 
BioSafe Coomassie stain overnight. The gel was removed from the stain, washed in deionized 
water, and imaged. 
 
Silver stain 
 
A silver stain was used to visualize the protein content of the fractions collected after identifying 
major peaks of the Heparin Ion-Exchange column. Samples from each fraction were run in a 7.5% 
polyacrylamide SDS-PAGE gel. The gel was then transferred to a solution of 50% methanol for 
10 minutes, then a 5% methanol solution for 10 minutes, a solution of 35 mM DTT for five 
minutes, and then a solution of .006M silver nitrate for 10 minutes. The gel was developed using 
a solution of 280 mM sodium carbonate anhydrous and quenched using powdered citric acid 
monohydrate. 
 
Western blot 
 
A western blot was used to confirm the presence of the final sample of Cas9. SDS-PAGE was run 
using a 7.5% polyacrylamide gel. The gel was transferred onto a nitrocellulose membrane at 0.25 
mAmps and 100 V for 1 hour. The nitrocellulose membrane was blocked in 5% milk in TBST. 
The primary antibodies were then diluted in 5% milk in TBST 1:500 and the nitrocellulose 
membrane was left to incubate overnight. The primary antibody was an Anti-Cas9 purified mouse 
monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% 
sodium azide from Millipore (MAC 133). After incubating in the primary overnight, the membrane 
was washed using a TBST wash buffer for three sessions ten minutes long each. Secondary mouse 
antibody bound with horseradish peroxidase was diluted 1:5000 in 5% milk in TBST. The 
nitrocellulose membrane incubated in the secondary antibody for 45 minutes before being washed 
for 10 minutes three times. The nitrocellulose membrane was then developed using peroxidase 
substrate for enhanced chemiluminescence (ECL). 
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Appendix 
 
 
 
 
Appendix A. Map of pMJ915 plasmid. 
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Appendix B. First growth curve of Rosetta 2 (DE3) cells and induction time. 
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Appendix C. Second growth curve of Rosetta 2 (DE3) cells and induction time. 
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